key: cord-0268517-eblosx3v authors: Ghezzi, C. E.; Hartigan, D. R.; Hardick, J.; Gore, R.; Adelfio, M.; Diaz, A. R.; McGuiness, P. D.; Robinson, M. L.; Buchholz, B. O.; Manabe, Y. C. L. title: Preclinical and clinical validation of a novel injected molded swab for molecular assay detection of SARS-CoV-2 virus date: 2021-10-26 journal: nan DOI: 10.1101/2021.10.19.21265200 sha: 8ff62f74b74c33dedf6a4831ad14de3ce2b69c03 doc_id: 268517 cord_uid: eblosx3v During the COVID-19 public health emergency, many actions have been undertaken to help ensure that patients and health care providers had timely and continued access to high-quality medical devices to respond effectively. The development and validation of new testing supplies and equipment, including collection swab, help expand the availability and capability for various diagnostic, therapeutic, and protective medical devices in high demand during the COVID-19 emergency. Here, we report the validation of a new injection-molded anterior nasal swab, ClearTip, that was experimentally validated in a laboratory setting as well as in independent clinical studies in comparison to gold standard flocked swabs. We have also developed an in vitro anterior nasal tissue model, that offers an efficient and clinically relevant validation tool to replicate with high fidelity the clinical swabbing workflow, while being accessible, safe, reproducible, time and cost effective. ClearTi displayed a greater efficiency of release of inactivated virus in the benchtop model, confirmed by greater ability to report positive samples in a clinical study in comparison to flocked swabs. We also quantified in multi-center pre-clinical and clinical studies the detection of biological materials, as proxy for viral material, that showed a statistically significant difference in one study and a slight reduction in performance in comparison to flocked swabs. Taken together these results underscore the compelling benefits of non-absorbent injected molded anterior nasal swab for COVID-19 detection, comparable to standard flocked swabs. Injection-molded swabs, as ClearTip, could have the potential to support future swab shortage, due to its manufacturing advantages, while offering benefits in comparison to highly absorbent swabs in terms comfort, limited volume collection, and potential multiple usage. The emergence of SARS-CoV-2 and the subsequent COVID-19 pandemic has resulted in approximately 200 million cases globally (1) . The long incubation period as well as the high prevalence of asymptomatic carrier transmission are prominent factors for the high transmission rate of SARS-CoV-2 (2) . Thus, efficient and reliable detection of infectious carriers through large-scale surveillance is critical to limit further spreading of the disease, particularly as many countries experience multiple waves of infections. Despite effective vaccines, continued global propagation of variants with efficient transmission dynamics even in vaccinated hosts increases the need to provide easily accessible testing on a wide variety of platforms. A nasopharyngeal (NP) swab is the gold standard sampling method to detect SARS-CoV-2, as recommended by the World Health Organization (WHO) (3) . Sample collection with NP swab is performed by trained professionals, transferred into transport media, and then processed via RNA purification and RT-qPCR, or other FDA approved methods. NP swabs are 15 cm long to reach the posterior nasopharynx, with a head diameter between 1 to 3.2 mm made from short synthetic threads, flock, or spun fibers (4) . The NP collection process is often reported as uncomfortable (5) . Due to supply chain limitations and increased demand, anterior nasal (AN) specimens have been successfully adopted as an effective alternative to solve the NP swab shortage (6) , and nasal swabs have been found to be equivalent to NP swabs for the detection of SARS-CoV-2, as studies have indicated high sensitivity and specificity for that sample type (7) . AN swabs offers similar testing sensitivity to NP swabs, while they are easier to administer and more comfortable for the patients, supporting its use in large-scale screening testing (5) . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 26, 2021. ; https://doi.org/10.1101/2021. 10.19.21265200 doi: medRxiv preprint New swab production methods have been explored to address the increase in demand for nasal swabs. 3D printed and injected molded swabs displayed performance comparable to standard flocked swabs (4, 8) , while offering high throughput, cost effective alternatives (8, 9) . In addition, a non-absorbent swab would allow to collected samples in limited volumes and to elute them into smaller volume of transport media, in comparison to standard absorbent swab, resulting in greater sample concentration and subsequent increase in sensitivity in viral RNA detection. To validate new swabs, innovative experimental procedures are needed to streamline this process. We evaluated the performance of the novel ClearTip™ (Yukon Medical, Durham, NC) injected-molded swab in comparison to traditional flocked nasal swabs. Preclinical validation was performed with an innovative in vitro tissue model to mimic the soft tissue structure as well as the viscous mucous component of the nasal passage. We hypothesized that the simulation of such tissue properties will provide a bench top validation to further support subsequent clinical studies. Finally, we evaluated the performance of the ClearTip™ injected-molded swab in comparison to traditional flocked nasal swabs in accurately collecting patient samples as well as detecting SARS-CoV-2 in two independent clinical studies. Anterior nasal, mid-turbinate, and nasopharyngeal injected molded swabs were designed, produced, and manufactured by Yukon Medical (Figure 1 ). These swabs were then compared to commercially available flocked swabs (Steripack and Copan). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. A nasal tissue model was developed to perform in vitro pre-clinical studies to quantify swab pick-up and release of inactivated SARS-CoV-2 virus from a physiologically relevant nasal mucosa. The nasal tissue model was comprised of a natural sponge made of cellulose (7456T-C41, 3M, Saint Paul, MN, USA) to mimic the soft tissue nature. It was prepared with hollow punchers in a cylindrical structure with an external and internal diameter of 2.5 and 0.875 mm, respectively, and 26 mm in overall length. To confine and retain the mucus, the tissue model was inserted in a polyvinyl chloride external tubing (Everbilt). The sponge was disinfected in subsequent washes of 10% bleach, 70% ethanol, deionized water, and then autoclaved. Before mucus saturation, the model was left to dry overnight is a biological hood. The mucus mimicking solution was prepared from a 2 wt% polyethylene oxide solution (CAS#: 25322-68-3 Acros Organics LOT#: A0403177), that has been previously shown to have similar viscosities to healthy nasal mucus (10, 11) . The anterior nasal tissue model was then saturated with 4.5 ml of the physiologically relevant mucus solution. To quantify swab uptake, the anterior nasal tissue model was saturated with the physiologically relevant mucus solution and the following swabbing procedure was utilized. Each swab was inserted into the model until resistance was encountered, twisted around the nasal model surfaces five times, held in place for 15 seconds, and then removed. The pick-up swab quantification was performed by gravimetrical analysis for the ClearTipÔ NP and ClearTipÔ MT/N swabs in comparison to commercially available flocked swabs (Steripack), and the weight of each swab All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 26, 2021. ; https://doi.org/10.1101/2021.10.19.21265200 doi: medRxiv preprint (N=5) was recorded before and after the swabbing procedure, and reported as mass uptake, for three independent experiments. To quantify swab release, the anterior nasal tissue model was saturated with the physiologically relevant mucus solution spiked at the concentration of 10 6 copies/ml of heat-inactivated SARS-CoV-2, USA-WA1/2020 (NR-52286, BEI Resources, ATCC, USA) and the swabbing procedure in the bench model was performed, as described above. After the procedure, the swab was Laboratory staff were approached regarding volunteering for a self-sampling study. Volunteers (N=8) were provided with one Copan FLOQSwabs 220250 Regular, one ClearTipÔ swab and two 15ml conical tubes containing 3ml of VTM. Each volunteer was asked to utilize All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 26, 2021. ; https://doi.org/10.1101/2021.10.19.21265200 doi: medRxiv preprint the flocked swab in their right nasal cavity and the ClearTipÔ in their left nasal cavity. Sampling for both swab types was performed identically by inserting the swab until resistance was noticed, the swabs were rotated 5 times, and then removed and placed into the separate tubes of VTM. Following swabbing, each tube of VTM was utilized to perform cell counts with the Countess II (Life Technologies, Foster City, CA). Briefly, 10 µl of VTM from each tube was mixed with 10 µl Trypan Blue (Life Technologies), and 10 µl of the mixture was loaded into a Countess II slide. Cell counts were performed utilizing the Countess II default setting. Following cell counting, 200 µl of VTM from each tube was extracted for RT-qPCR analysis utilizing the Nuclisense EasyMag (Biomeriuex, Durham, NC) following manufacturer instructions. Postextraction, each sample was analyzed for total DNA concentration utilizing the NanoDrop One (Thermofisher Scientific, Waltham, MA) per manufacturer instructions. Samples were subsequently analyzed for RNAseP utilizing the CDC nCOV_2019 RT-qPCR assay per manufacturer instructions. Cell counts, total DNA concentration and RNASeP Ct values were utilized to discern differences in the quantity of cells released by each swab type. To evaluate ClearTipÔ versus flocked swab performance, two clinical studies were carried out to assess pick-up and release of each swab type by quantifying human RNase P expression, as well as N1 and N2 when the subjects were positive. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Participants were already enrolled into a surveillance program at University of Massachusetts Lowell (UML), and were asked to be swabbed with the ClearTipÔ N swab as well as with a commercially available comparator (Steripack), and to complete a short survey on the comfort of the swabs. Swabs were collected in VTM in a 15-ml conical tube, transported to the RADx Validation Core Lab at UML, stored at 4°C identically to clinical samples, and tested the following day. Sample collection was performed by trained nursing personnel at the UML Wellness Center. This study was reviewed and approved by the institutional review board of UML (protocol number 20-149-BUC-FUL). Participants were healthy individuals, as self-reported and determined by a screening asked during recruitment consent, and already enrolled into the surveillance program at UML. Patient AN samples (N=47) were collected with a ClearTip™ swab within seven days of a validated negative SARS-CoV-2 test result from a sample collected with a CLIA use approved Class I exempt nasal swab and tested in an approved RT-qPCR assay by a CLIA-certified clinical lab. Adults over 18 years of age were given a participant information sheet by study staff and asked whether they would agree to being swabbed with an experimental swab by a trained nurse to the control swab required for testing, and also complete a short comfort survey. ClearTipÔInjected molded swabs were individually packaged and autoclaved for sterilization according to manufacturer protocols. Swabbing was performed per the standard protocol in both nostril for each swab. After swabbing both nostrils, the subject returned to the study coordinator(s). Participants then completed a short survey on the relative comfort of the two All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Participants, enrolled in the study performed at Washington University School of Medicine, were recruited as symptomatic at a walk-in clinic. They were all tested first with NP swabs and then randomly swabbed nasally first with the ClearTipÔ N swab or commercially available comparator (Copan). Swabs were eluted for 10 minutes in M4-RT universal transporting medium (UTM). Sample collection was performed by trained nursing personnel at the Washington University School of Medicine. This study was reviewed and approved by the institutional review board of Washington University School of Medicine (protocol number 7453). Participants were symptomatic individuals, as self-reported and determined by a screening asked (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 26, 2021. ; https://doi.org/10.1101/2021.10.19.21265200 doi: medRxiv preprint of age were given an informed consent form by study staff and asked whether they would agree to being swabbed with an experimental swab by a trained nurse to the control swab required for testing. ClearTipÔ swabs were individually packaged and autoclaved for sterilization according to Paired t-tests and equivalence testing using a two one-sided t-test (TOST) of equivalence using appropriate equivalence margins were performed with a p<0.05 significance threshold (12). Negative predictive value (NPV) was calculated with a weighted generalized score method (13). Paired t-test, equivalence tests and the weighted generalized score method were analyzed using SAS 9.4 (SAS Institute, Inc., Cary NC). Additional Student's T-test (T-test) with a p-value of < All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. An anterior nasal tissue model was developed to quantify the sample uptake and release from anterior nasal swabs (Figure 2A ). The tissue model was designed with a cellulose sponge to mimic the nasal soft tissue, and saturated with a synthetic nasal mucus spiked with inactivated SARS-CoV-2 virus and was designed to mimic clinical nasal swab to facilitate an evaluation of swab performance. The swab uptake was quantified by gravimetric analysis after the benchtop swabbing procedure. The ClearTip™ swab displayed a significantly lower uptake of synthetic mucus in comparison to control flocked swabs (p<0.05). ClearTip™ demonstrated more than 20fold reduction in swab uptake in comparison to the control swab ( Figure 2B ). The ability of the swabs to release biological materials was quantified by performing the swabbing workflow with the nasal tissue model loaded with inactivated SARS-CoV-2 virus. Swabs were then collected into viral transport media, and the virus released from the swab was quantified via RT-qPCR, according to CDC guidelines. ClearTip™ displayed a significantly lower cycle time (e.g., more virus) in detecting inactivated SARS-CoV-2 virus, in comparison to flocked control swab (p<0.05). The reduction in cycle time for the ClearTip™ swab support greater viral recovery in comparison to flocked control ( Figure 2C ). Results from the preclinical self-sampling study are summarized in Figure 3 . Numbers of total cells, live cells and dead cells were quantified, as well as the quantification of DNA content and RNase P expression. Overall, samples that were from self-sampling with flocked swabs produced All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 26, 2021. ; https://doi.org/10.1101/2021.10.19.21265200 doi: medRxiv preprint higher live cell counts ( Figure 3B ), greater DNA concentration ( Figure 3D ) and lower RNAseP Ct values ( Figure 3E ) than the samples from ClearTipÔ self-sampling (p<0.05). Quantification of the total number of cells (Figure 3 A) and dead cells ( Figure 3C) were not statistically significantly different at the 0.05 level. While the t-test found non-significant differences (p=0.0509 and p=0.2920, respectively for total and dead cells), the underpowered sample size and large variation contributed to the non-equivalence result, from the equivalence test. To quantitively compare the performance of the ClearTip™, 47 participants self-collected nasal samples using ClearTip™ in comparison to a flocked CLIA approved swab ( Figure 4A) . None of the participants tested positive in this surveillance program, thus, the expression of RNase P was used to compare the efficiency of each swab to pick up human biological material. ClearTip™ demonstrated a significantly higher RT-qPCR cycle time in comparison to the flocked control swab, Steripack (p<0.05). Quantitatively, we reported a 2-cycle difference for the two compared swabs, that was found statistically different. In the second clinical study, 38 participants were collected using ClearTip™ in comparison to a flocked CLIA approved swab ( Figure 4B ). ClearTip™ displayed no differences in comparison to the CLIA approved swab, Copan (p=0.9549). In addition, an equivalence test with a margin of 1 determined that the swabs measured the same value of RNAseP. Using an RNAaseP RT-PCR, there was no difference between ClearTip™ and the Copan swabs. Of the 9 individuals (of 38 total) who tested NP swab positive in a CLIA-certified reference lab (Figure 5 ), the ClearTip™ swab confirmed 78% of positive cases detected with an NP CLIA use approved flocked swab for N gene detection, while the Copan swab confirmed only 22% of the cases. Based on a weighted All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. In the first clinical study, participants scored the comfort of the two swabs over a 5-point Likert scale ( Figure 6A ). The mean paired difference in swab comfort was reported 0.3 ( Figure 6B ). ClearTip™ was found equivalent to the flocked CLIA approved swab with a paired two onesided t-test (TOST) of equivalence using an equivalence margin of 1 (p<0.05). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. During the peaks in the pandemic, swab shortages at hospital across the United States and worldwide have been reported (14), prompting the need to develop new swab prototypes with comparable performance and capable of high-volume manufacturing, while being cost-efficient. Here, we report a new injection-molded anterior nasal swab, ClearTip™, that was experimentally validated in a laboratory setting as well as in independent clinical studies in comparison to gold standard flocked swabs. In vitro tissue models have been recently developed and extensively investigated, as they can mimic a wide range of the physical, structural, and biological characteristics of native tissues, and thus implemented to study in vitro physiological and pathological tissue conditions (15) (16) (17) (18) (19) . We report an anterior nasal tissue model, that mimics the architecture and structure of the native soft tissue, as well as the physical properties of the nasal mucus. In the anterior nasal tissue model, we quantified the ability of ClearTip™ to pick up artificial mucus in comparison to gold standard flocked swabs. ClearTip™ displayed more than 20 times less retention than a flocked swab. However, when we evaluated in vitro the capacity of ClearTip™ to release viral material, the injected molded swab displayed significantly greater inactivated virus release in comparison to flocked swabs. This suggests a much greater efficiency of release of inactivated virus from the ClearTip™ swab, that may offset the reduction in uptake in comparison to standard flocked swab. In clinical assessments, ClearTip™ showed variability in its ability to pick up and release cellular material as a proxy for performance in COVID-19 testing. Measurements of cell population, DNA concentration and RNaseP quantification showed equivalence in one study and a reduction in performance in comparison to flocked swabs in a separate assessment suggesting All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Copan anterior nasal swabs used in these studies. Scale bar = 10 mm. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 26, 2021. ; https://doi.org/10.1101/2021.10.19.21265200 doi: medRxiv preprint Coronavirus Cases 2021 COVID-19: asymptomatic carrier transmission is an underestimated problem Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases. Interim guidance Open Development and Clinical Validation of Multiple 3D-Printed Nasopharyngeal Collection Swabs: Rapid Resolution of a Critical COVID-19 Testing Bottleneck Nasopharyngeal swab-induced pain for SARS-CoV-2 screening: A randomised controlled trial of conventional and self-swabbing Detection of Severe Acute Respiratory Syndrome Coronavirus 2 on Self-Collected Saliva or Anterior Nasal Specimens Compared With Healthcare Personnel-Collected Nasopharyngeal Specimens Nasal Swab Sampling for SARS-CoV-2: a Convenient Alternative in Times of Nasopharyngeal Swab Shortage Accessioning and automation compatible anterior nares swab design Clinical Diagnostic Study of a Novel Injection Molded Swab for SARS Detection of respiratory viruses in sputum from adults by use of automated multiplex PCR Enhanced oral absorption and anticancer efficacy of cabazitaxel by overcoming intestinal mucus and epithelium barriers using surface polyethylene oxide (PEO) decorated positively charged polymer-lipid hybrid nanoparticles Kosinski AS. A weighted generalized score statistic for comparison of predictive values of diagnostic tests Programmable 3D silk bone marrow niche for platelet generation ex vivo and modeling of megakaryopoiesis pathologies Multilayered dense collagen-silk fibroin hybrid: a platform for mesenchymal stem cell differentiation towards chondrogenic and osteogenic lineages Immediate production of a tubular dense collagen construct with bioinspired mechanical properties 3D Functional Corneal Stromal Tissue Equivalent Based on Corneal Stromal Stem Cells and Multi-Layered Silk Film Architecture All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder This study was funded by the NIH RADx-Tech program under 3U54HL143541-02S1, 3U54HL143541-02S2 and U54EB007958-12S1. The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the National Institute of All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.